Science and Research
CLN-0046: A Study of OTX-TKI for Intravitreal Use in Subjects With Neovascular Age-Related Macular Degeneration (AMD)
The purpose of this study is to evaluate how safe, tolerable and effective the OTX–TKI is in treating wet age-related macular degeneration (AMD) with two different doses of axitinib.
Overview
This study aims to assess a new implant called OTX–TKI, which contains the study drug axitinib.
The purpose of this study is to evaluate how safe, tolerable and effective the OTX–TKI is in treating wet age-related macular degeneration (AMD) with two different doses of axitinib.
The OTX-TKI implant is injected into the vitreous of the eye (the jelly-like substance that fills the eyeball), and monitored until the implants slowly break down and are eventually cleared from the eye.
Regular visits are scheduled for a minimum of 9 months from the implant date.
- Principal Investigator
Associate Professor Sanj Wickremasinghe
This study aims to assess a new implant called OTX–TKI, which contains the study drug axitinib.
The purpose of this study is to evaluate how safe, tolerable and effective the OTX–TKI is in treating wet age-related macular degeneration (AMD) with two different doses of axitinib.
The OTX-TKI implant is injected into the vitreous of the eye (the jelly-like substance that fills the eyeball), and monitored until the implants slowly break down and are eventually cleared from the eye.
Regular visits are scheduled for a minimum of 9 months from the implant date.
- Principal Investigator
Learn more
View this study at ClinicalTrials.gov
This international database listing provides more detailed information about this study.